Prosecution Insights
Last updated: April 19, 2026

Remix Therapeutics Inc.

10 pending office actions

Portfolio Summary

10
Total Pending OAs
6
Final Rejections
4
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18033748 OLIGONUCLEOTIDES USEFUL FOR MODULATION OF SPLICING CHONG, KIMBERLY 1636 Non-Final OA Apr 25, 2023
18014059 2-(INDAZOL-5-YL)-6-(PIPERIDIN-4-YL)-1,7-NAPHTHYRIDINE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS FOR SPLICING NUCLEIC ACIDS AND FOR THE TRE MCDOWELL, BRIAN E 1624 Non-Final OA Dec 30, 2022
17917734 COMPOUNDS AND METHODS FOR MODULATING SPLICING BELL, SARA ELIZABETH 1625 Final Rejection Oct 07, 2022
17917729 COMPOUNDS AND METHODS FOR MODULATING SPLICING NESTOR, DONNA MICHELLE 1627 Final Rejection Oct 07, 2022
17917842 COMPOUNDS AND METHODS FOR MODULATING SPLICING KUCKLA, ANNA GRACE 1626 Final Rejection Oct 07, 2022
17802827 COMPOUNDS AND METHODS FOR MODULATING SPLICING COUGHLIN, MATTHEW P 1626 Final Rejection Aug 26, 2022
17802719 HETEROCYCLIC AMIDES AND THEIR USE FOR MODULATING SPLICING HASTINGS, ALISON AZAR 1627 Final Rejection Aug 26, 2022
17802863 COMPOUNDS AND METHODS FOR MODULATING SPLICING NOTTINGHAM, KYLE GREGORY 1621 Final Rejection Aug 26, 2022
17802833 FUSED BICYCLIC COMPOUNDS USEFUL FOR MODULATING NUCLEIC ACID SPLICING CHICKS, ASHLI ARIANA 1626 Non-Final OA Aug 26, 2022
17802702 PYRIDAZINE DERIVATIVES FOR MODULATING NUCLEIC ACID SPLICING MAHLUM, JONATHAN DAVIS 1625 Non-Final OA Aug 26, 2022

Managing Remix Therapeutics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month